Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH

01-02-2017 | Image

Figure 4: Recurrent genetic alterations affecting key pathways involved in multiple myeloma.

Signalling pathways and processes known to be affected in multiple myeloma are involved in the NF-κB, MAPK, plasma-cell differentiation, cell cycle and DNA-damage repair pathways. In this diagram, frequently mutated genes with well-established roles in these signalling pathways have been depicted representing the proteins they encode.

print
PRINT
Image Credits